FDA panel questions effectiveness of Grail's early-cancer detection test

FDA's Molecular and Clinical Genetics Panel and agency officials raised concerns about Grail's next-generation sequencing test designed to detect multiple cancers early in adults over 50.

The advisory committee highlighted uncertainty over how well the test performs across the various cancer types it targets.

These questions may delay or complicate any future regulatory approval for the test.